Regal Investment Advisors LLC Has $288,000 Stock Position in GSK plc (NYSE:GSK)

Regal Investment Advisors LLC lifted its holdings in GSK plc (NYSE:GSK) by 7.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,503 shares of the pharmaceutical company’s stock after acquiring an additional 597 shares during the period. Regal Investment Advisors LLC’s holdings in GSK were worth $288,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Dodge & Cox raised its holdings in GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock valued at $2,314,672,000 after acquiring an additional 353,749 shares in the last quarter. Bridgewater Associates LP raised its stake in GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company’s stock valued at $76,017,000 after purchasing an additional 1,281,855 shares in the last quarter. Guggenheim Capital LLC lifted its position in GSK by 6.2% during the fourth quarter. Guggenheim Capital LLC now owns 15,053 shares of the pharmaceutical company’s stock worth $509,000 after purchasing an additional 881 shares during the period. Causeway Capital Management LLC grew its stake in GSK by 20.0% during the fourth quarter. Causeway Capital Management LLC now owns 1,076,580 shares of the pharmaceutical company’s stock worth $36,410,000 after buying an additional 179,174 shares in the last quarter. Finally, Mariner LLC increased its holdings in GSK by 0.6% in the 4th quarter. Mariner LLC now owns 116,961 shares of the pharmaceutical company’s stock valued at $3,955,000 after buying an additional 736 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Trading Up 1.5 %

Shares of GSK stock opened at $35.92 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market capitalization of $74.10 billion, a P/E ratio of 22.59, a P/E/G ratio of 1.12 and a beta of 0.56. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The stock’s fifty day simple moving average is $37.44 and its 200 day simple moving average is $36.14.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, sell-side analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were paid a $0.3932 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.38%. The ex-dividend date of this dividend was Friday, February 21st. GSK’s payout ratio is currently 100.63%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on GSK shares. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday. They issued a “neutral” rating and a $35.25 price objective on the stock. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Eight research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.